![Swamy Yeleswaram](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 10 M $ in data 31/05/2026
Swamy Yeleswaram was the founder of Incyte Corp., founded in 2002, and held the title of Group Vice President-Drug Metabolism from 2016 to 2022.
Dr. Yeleswaram currently holds the position of Chief Development Officer at Rapport Therapeutics, Inc. since 2023.
Dr. Yeleswaram's education includes a doctorate from the University of British Columbia, a graduate degree from Banaras Hindu University, and an undergraduate degree from Madras Medical College.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/04/2026 | 246.426 ( 0,52% ) | 10 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2023 |
| Società | Posizione | Fine |
|---|---|---|
| INCYTE CORPORATION | Fondatore | 01/08/2022 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Banaras Hindu University
 Banaras Hindu University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madras Medical College
 Madras Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
